S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
NASDAQ:MRNS

Marinus Pharmaceuticals - MRNS Earnings Date, Estimates & Call Transcripts

$5.47
-0.22 (-3.87%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.36
$5.87
50-Day Range
$4.09
$6.21
52-Week Range
$3.97
$13.58
Volume
293,375 shs
Average Volume
322,646 shs
Market Capitalization
$203.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.14

Earnings Summary

Upcoming
Earnings Date
Aug. 11Confirmed
Actual EPS
(May. 12)
-$0.52 Beat By $0.35
Consensus EPS
(May. 12)
-$0.87
Last Year's Q2 EPS
(5/17/2021)
-$0.74
Skip Charts & View Estimated and Actual Earnings Data

MRNS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRNS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Marinus Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20225($0.94)($0.07)($0.69)
Q2 20225($0.95)$1.47($0.38)
Q3 20225($1.07)($0.79)($0.97)
Q4 20225($1.12)($0.62)($0.94)
FY 202220($4.08)($0.01)($2.99)
Q1 20231($1.12)($1.12)($1.12)
Q2 20231($1.14)($1.14)($1.14)
Q3 20231($0.90)($0.90)($0.90)
Q4 20231($0.92)($0.92)($0.92)
FY 20234($4.08)($4.08)($4.08)

MRNS Earnings Date and Information

Marinus Pharmaceuticals last announced its quarterly earnings results on May 12th, 2022. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.35. The business had revenue of $14.19 million for the quarter, compared to the consensus estimate of $2.19 million. Marinus Pharmaceuticals has generated ($2.47) earnings per share over the last year (($2.47) diluted earnings per share). Earnings for Marinus Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($3.76) per share. Marinus Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, August 11th, 2022. Marinus Pharmaceuticals will be holding an earnings conference call on Thursday, August 11th at 8:30 AM Eastern. Interested parties can register for or listen to the call..

Marinus Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/11/2022
(Confirmed)
 ($0.93)       
5/12/2022Q1 2022($0.87)($0.52)+$0.35($0.52)$2.19 million$14.19 million
3/21/2022Q4 2021($0.81)($0.77)+$0.04($0.77)$2.64 million$1.52 million    
11/9/20219/30/2021($0.76)($0.53)+$0.23($0.53)$2.32 million$10.11 million    
8/10/20216/30/2021($0.68)($0.65)+$0.03($0.65)$2.57 million$1.91 million    
5/17/20213/31/2021($0.46)($0.74)($0.28)($0.74)$2.61 million$1.81 million  
3/8/202112/31/2020($0.52)($0.55)($0.03)($0.55)$1.77 million$1.55 million  
11/9/20209/30/2020($0.60)($0.51)+$0.09($0.51)  
8/6/20206/30/2020($0.76)($0.64)+$0.12($0.16)
5/4/20203/31/2020($0.64)($1.28)($0.64)($0.32)  
3/16/202012/31/2019($0.84)($1.00)($0.16)($0.26)
11/6/2019Q3($0.9480)($1.04)($0.0920)($0.26)
8/8/2019Q2 2019($0.9360)($0.96)($0.0240)($0.24)
5/1/2019Q1 2019($0.8480)($0.96)($0.1120)($0.24)
3/11/201912/31/2018($1.04)($0.96)+$0.08($0.24)
10/29/20189/30/2018($0.84)($1.08)($0.24)($0.27)
8/2/2018Q2 2018($0.60)($0.96)($0.36)($0.24)
5/2/2018Q1 2018($0.64)($0.60)+$0.04($0.15)
3/6/2018Q4 2017($0.52)($0.80)($0.28)($0.20)
10/31/2017Q3 2017($0.68)($0.60)+$0.08($0.15)
8/1/2017Q2 2017($1.08)($0.84)+$0.24($0.21)
5/1/2017Q1 2017($1.28)($1.04)+$0.24($0.26)
3/13/2017Q4 2016($1.32)($1.24)+$0.08($0.31)
11/3/2016Q3($1.72)($1.32)+$0.40($0.33)
8/9/2016Q2($1.52)($1.84)($0.32)($0.46)
5/2/2016Q1 2016($1.64)($1.48)+$0.16($0.37)
3/7/2016Q416($1.52)($1.80)($0.28)($0.45)
10/29/2015Q3 2015($2.04)($1.40)+$0.64($0.35)
8/4/2015Q2 2015($2.04)($1.48)+$0.56($0.37)
5/11/2015Q1 2015($1.88)($2.00)($0.12)($0.50)
3/12/2015Q4 2014($1.04)($1.04)($0.26)
11/13/2014Q3 14($2.00)($1.20)+$0.80($0.38)












Marinus Pharmaceuticals Earnings - Frequently Asked Questions

When is Marinus Pharmaceuticals's earnings date?

Marinus Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, August 11th, 2022. Learn more on MRNS's earnings history.

Did Marinus Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Marinus Pharmaceuticals (NASDAQ:MRNS) reported ($0.52) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.87) by $0.35. Learn more on analysts' earnings estimate vs. MRNS's actual earnings.

How much revenue does Marinus Pharmaceuticals generate each year?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a recorded annual revenue of $15.35 million.

How much profit does Marinus Pharmaceuticals generate each year?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a recorded net income of -$98.78 million. MRNS has generated -$2.47 earnings per share over the last four quarters.

What is Marinus Pharmaceuticals's EPS forecast for next year?

Marinus Pharmaceuticals's earnings are expected to decrease from ($2.33) per share to ($3.76) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:MRNS) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.